Smart & Biggar uncovers and maximizes intellectual property and technology assets for our clients.
Today’s fast-paced innovation economy demands a higher level of expertise and attention to detail when it comes to IP strategy and protection. With over 125 lawyers, patent agents and trademark agents collaborating across five Canadian offices, Smart & Biggar is trusted by the world’s leading innovators to find value in their IP rights.
As market leaders in IP, Smart & Biggar’s team is on the pulse when it comes to the latest developments and the wider industry changes that impact our clients. To stay informed, visit smartbiggar.ca/insights, including access to our RxIP Update (smartbiggar.ca/insights/rx-ip-updates), a monthly digest of the latest decisions and law surrounding the life sciences and pharmaceutical industries.
The Therapeutic Products Directorate, the Biologic and Radiopharmaceutical Drugs Directorate and the Natural and Non-Prescription Health Products Directorate have released their Drug Submission Performance Annual Reports ...
Update: On September 1, 2020, BRDD revised its
Report to correct the "Biosimilars: Market
Authorizations" tables.
The Therapeutic Products Directorate (TPD), the Biologic and Radiopharmaceutical
Drugs Directorate (BRDD) (formerly BGTD) and the Natural and
Non-Prescription Health Products Directorate (NNHPD) have released their Drug Submission
Performance Annual Reports for Fiscal Year 2019-2020. The reports
contain information regarding pharmaceutical, biologic and
radiopharmaceutical, and non-prescription and disinfectant drug
submission review activity over five consecutive fiscal years
(April 1 to March 31) from 2015-2016 to 2019-2020.
The preceding is intended as a timely update on Canadian
intellectual property and technology law. The content is
informational only and does not constitute legal or professional
advice. To obtain such advice, please communicate with our offices
directly.
